Obesity Surgery

, Volume 24, Issue 11, pp 1835–1842

Long-Term Effects of Laparoscopic Roux-en-Y Gastric Bypass on Diabetes Mellitus, Hypertension and Dyslipidaemia in Morbidly Obese Patients

  • K. Dogan
  • B. Betzel
  • J. Homan
  • E. O. Aarts
  • N. Ploeger
  • H. de Boer
  • Th. J. Aufenacker
  • C. J. H. M. van Laarhoven
  • I. M. C. Janssen
  • F. J. Berends
Original Contributions

Abstract

Background

Severely obese patients have an increased risk for developing metabolic complications such as type 2 diabetes mellitus (T2DM), dyslipidaemia (DL) and hypertension (HT). The aim of the present study is to research the effect of a primary laparoscopic Roux-en-Y gastric bypass (LRYGB) on T2DM, HT and DL in the long-term.

Methods

Fifty-two out of 89 (58 %) adult severely obese patients with T2DM who had received a LRYGB between January 2000 and December 2008 were evaluated. Primary outcome of evaluation was remission of T2DM according to the definition of 2009 consensus statement. Complete remission was defined as achievement fasting plasma glucose (FPG) of <5.6 mmol/l (<100.8 mg/dL) and HbA1c <42 mmol/mol (<6.0 %)) without glucose-lowering medication for at least 1 year. Partial remission was defined as a FPG of 5.6–6.9 mmol/l (100.8–124.2 mg/dL) and HbA1c 42–48 mmol/mol (6.0–6.5 %), without glucose-lowering medication for at least 1 year. Remission of T2DM was considered if the patient met the criteria for complete or partial remission. Secondary outcomes were remission of HT, DL and changes in medication use.

Results

Patients had a mean age of 47.5 ± 9.6 years, body mass index of 46.6 ± 6.4 kg/m2 and a mean duration of T2DM of 6.1 ± 5.4 years at the time of surgery. The mean post-operative follow-up period was 6.9 ± 2.3 years. At the end of the follow-up, mean weight loss was 60 ± 24 % excess weight loss (EWL) and 26 ± 10 % total body weight loss (TBWL). Mean HbA1c level had significantly decreased from 64.8 ± 19.7 mmol/mol to 46.4 ± 12.9 mmol/l (p < 0.0001). Overall medication use was reduced from 85 % to 37 % of the patients (p < 0.0001), while the number of insulin users was reduced from 40 % to 6 % (p < 0.0001). Nineteen percent of the patients had a relapse of T2DM during follow-up. Pre-operative HbA1ac level (odds ratio 0.911, p = 0.020) and duration of T2DM (odds ratio 0.637, p = 0.010) were independent risk factors for failed remission of T2DM. The number of patients with HT was significantly reduced from 73 % to 54 % (p = 0.042), and number of patients with DL was non-significantly decreased from 71 % to 54 % (p = 0.068).

Conclusions

The laparoscopic RYGB operation results in a sustained EWL of 60 % (26 % TBWL) with 52 % long-term remission of T2DM. However, 19 % of the patients had a relapse of their T2DM. Furthermore, HT and DL improved markedly.

Keywords

Morbid obesity Bariatric surgery Roux-en-Y gastric bypass Diabetes mellitus type 2 Hypertension Dyslipidaemia 

References

  1. 1.
    Pedersen SD. Metabolic complications of obesity. Best Pract Res Clin Endocrinol Metab. 2013;27(2):179–93.PubMedCrossRefGoogle Scholar
  2. 2.
    Unwin N, Gan D, Whiting D. The IDF diabetes atlas: providing evidence, raising awareness and promoting action. Diabetes Res Clin Pract. 2010;87(1):2–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434–44.PubMedCrossRefGoogle Scholar
  4. 4.
    Dirksen C, Jorgensen NB, Bojsen-Moller KN, et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia. 2012;55(7):1890–901.PubMedCrossRefGoogle Scholar
  5. 5.
    Jazet IM, Schaart G, Gastaldelli A, et al. Loss of 50% of excess weight using a very low energy diet improves insulin-stimulated glucose disposal and skeletal muscle insulin signalling in obese insulin-treated type 2 diabetic patients. Diabetologia. 2008;51(2):309–19.PubMedCrossRefGoogle Scholar
  6. 6.
    Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(3):193–205.PubMedCrossRefGoogle Scholar
  7. 7.
    Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, et al. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes. 2003;52(5):1098–103.PubMedCrossRefGoogle Scholar
  8. 8.
    Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000;23(10):1499–504.PubMedCrossRefGoogle Scholar
  9. 9.
    Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.PubMedCrossRefGoogle Scholar
  10. 10.
    Colquitt JL, Picot J, Loveman E, et al. Surgery for obesity. Cochrane Database Syst Rev. 2009;2, CD003641.PubMedGoogle Scholar
  11. 11.
    Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–56. e5.PubMedCrossRefGoogle Scholar
  12. 12.
    Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013;23(4):427–36.PubMedCrossRefGoogle Scholar
  13. 13.
    Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366(17):1577–85.PubMedCrossRefGoogle Scholar
  14. 14.
    Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567–76.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Dixon JB, Zimmet P, Alberti KG, et al. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Arq Bras Endocrinol Metab. 2011;55(6):367–82.CrossRefGoogle Scholar
  16. 16.
    Rubino F, Kaplan LM, Schauer PR, et al. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010;251(3):399–405.PubMedCrossRefGoogle Scholar
  17. 17.
    NIH Conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 1991;115(12):956–61.CrossRefGoogle Scholar
  18. 18.
    Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133–5.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Hoelzel W, Weykamp C, Jeppsson JO, et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem. 2004;50(1):166–74.PubMedCrossRefGoogle Scholar
  20. 20.
    Haffner SM, American Diabetes A. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27 Suppl 1:S68–71.PubMedGoogle Scholar
  21. 21.
    WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment.Google Scholar
  22. 22.
    Aarts EO, van Wageningen B, Janssen IM, et al. Prevalence of anemia and related deficiencies in the first year following laparoscopic gastric bypass for morbid obesity. J Obes. 2012;2012:193705.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309(21):2240–9.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Inabnet 3rd WB, Winegar DA, Sherif B, et al. Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. J Am Coll Surg. 2012;214(4):550–6. discussion 6-7.PubMedCrossRefGoogle Scholar
  25. 25.
    Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238(4):467–84. discussion 84-5.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Abbatini F, Rizzello M, Casella G, et al. Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes. Surg Endosc. 2010;24(5):1005–10.PubMedCrossRefGoogle Scholar
  27. 27.
    Jimenez A, Casamitjana R, Flores L, et al. GLP-1 and the long-term outcome of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery in morbidly obese subjects. Ann Surg. 2013;257(5):894–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Jimenez A, Casamitjana R, Flores L, et al. Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects. Ann Surg. 2012;256(6):1023–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Yamaguchi CM, Faintuch J, Hayashi SY, et al. Refractory and new-onset diabetes more than 5 years after gastric bypass for morbid obesity. Surg Endosc. 2012;26(10):2843–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Zimmet P, Alberti KG. Surgery or medical therapy for obese patients with type 2 diabetes? N Engl J Med. 2012;366(17):1635–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Higa K, Ho T, Tercero F, et al. Laparoscopic Roux-en-Y gastric bypass: 10-year follow-up. Surg Obes Relat Dis. 2011;7(4):516–25.PubMedCrossRefGoogle Scholar
  32. 32.
    Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.PubMedCrossRefGoogle Scholar
  33. 33.
    Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308(11):1122–31.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Chikunguwo SM, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2010;6(3):254–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Hamza N, Abbas MH, Darwish A, et al. Predictors of remission of type 2 diabetes mellitus after laparoscopic gastric banding and bypass. Surg Obes Relat Dis. 2011;7(6):691–6.PubMedCrossRefGoogle Scholar
  36. 36.
    DiGiorgi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis. 2010;6(3):249–53.PubMedCrossRefGoogle Scholar
  37. 37.
    Dixon JB, Chuang LM, Chong K, et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes Care. 2013;36(1):20–6.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Aarts EO, Janssen J, Janssen IM, et al. Preoperative fasting plasma C-peptide level may help to predict diabetes outcome after gastric bypass surgery. Obes Surg. 2013;23(7):867–73.PubMedCrossRefGoogle Scholar
  39. 39.
    Lee WJ, Chong K, Ser KH, et al. C-Peptide predicts the remission of type 2 diabetes after bariatric surgery. Obes Surg. 2012;22(2):293–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Hall TC, Pellen MG, Sedman PC, et al. Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity. Obes Surg. 2010;20(9):1245–50.PubMedCrossRefGoogle Scholar
  41. 41.
    Laurino Neto RM, Herbella FA, Tauil RM, et al. Comorbidities remission after Roux-en-Y gastric bypass for morbid obesity is sustained in a long-term follow-up and correlates with weight regain. Obes Surg. 2012;22(10):1580–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Obeid A, Long J, Kakade M, et al. Laparoscopic Roux-en-Y gastric bypass: long term clinical outcomes. Surg Endosc. 2012;26(12):3515–20.PubMedCrossRefGoogle Scholar
  43. 43.
    Sugerman HJ, Wolfe LG, Sica DA, et al. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg. 2003;237(6):751–6. discussion 7-8.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • K. Dogan
    • 1
  • B. Betzel
    • 1
  • J. Homan
    • 1
  • E. O. Aarts
    • 1
  • N. Ploeger
    • 1
  • H. de Boer
    • 2
  • Th. J. Aufenacker
    • 1
  • C. J. H. M. van Laarhoven
    • 3
  • I. M. C. Janssen
    • 1
  • F. J. Berends
    • 1
  1. 1.Department of SurgeryRijnstate HospitalArnhemThe Netherlands
  2. 2.Internal MedicineRijnstate HospitalArnhemThe Netherlands
  3. 3.Department of SurgeryRadboud University Medical CentreNijmegenThe Netherlands

Personalised recommendations